EASD 2025 15 - 19 September 2025

REDEFINE 2: A randomised trial of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of adults with BMI ≥27 kg/m² and type 2 diabetes

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Obesity

Congress oral presentation

GLP-1 RA

CagriSema

PHASE 3 (RCT)

Are you a healthcare professional?